Home › Drug Codes › J Codes › J3389 · ZEVASKYN
Updated July 1st, 2026

ZEVASKYN J Code: J3389

Topical administration, prademagene zamikeracel, per treatment

Login to unlock all benchmarks
Medicare Payment Limit ?
Not published
CMS publishes none for Q3 2026
APC Payment Limit ?
$3,285,782.70
/ HCPCS billing unit · APC 0908
ASP ?
No current ASP
Not available for Q3 2026
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
1
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Topical administration, prademagene zamikeracel, per treatment
HCPCS Added Date January 1, 2026
Manufacturer Abeona Therapeutics Inc
Route of Administration Topical
Generic Status Single-Source; Branded
Dosage Form Cellular Sheet

About ZEVASKYN

Zevaskyn is a medication aligned to the HCPCS J Code: J3389 for billing, pricing, and reimbursement purposes in the United States. Classified under Genetic Disorder, it is administered via the topical route and manufactured by Abeona Therapeutics Inc.

Manufacturers, reach out to us to add more information.

NDC Code Information

1 NDC package is crosswalked to J3389. Package detail is available to logged-in subscribers.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
•••••-••••-•• Log in to view ZEVASKYN
Login to view 1 NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

ZEVASKYN Pricing & Reimbursement

J3389 Private Payer Reimbursement
$3,330.00 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna
Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

ZEVASKYN Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.
Access Full Report →

Frequently Asked Questions

Is there a manufacturer-published ZEVASKYN billing and coding guide?
Billing and coding information for ZEVASKYN can be found through Abeona Therapeutics Inc.. Visit Here →
Is there an available ZEVASKYN patient assistance program?
ZEVASKYN patient assistance information can be found through Abeona Therapeutics Inc.. Visit Here →
Where can I find ZEVASKYN prescribing information?
ZEVASKYN prescribing information can be found at the link below. Visit Here →
Where can I find ZEVASKYN side effect information?
ZEVASKYN side effect information can be found through MedlinePlus. Visit Here →
Does billing ZEVASKYN require JZ/JW wastage modifiers?
CMS does not include ZEVASKYN (J3389) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J3389. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to ZEVASKYN.

C9172BEQVEZInjection, fidanacogene elaparvovec-dzkt, per therapeutic dosePfizerAdded October 1, 2024C9309ItvismaInjection, onasemnogene abeparvovec-brve, per treatmentNovartis Gene TherapiesAdded April 1, 2026C9311WainuaInjection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)AstrazenecaAdded October 1, 2026J0222ONPATTROInjection, patisiran, 0.1 mgAlnylam PharmaceuticalsAdded October 1, 2019J0223GIVLAARIInjection, givosiran, 0.5 mgAlnylam PharmaceuticalsAdded July 1, 2020J0224OXLUMOInjection, lumasiran, 0.5 mgAlnylam PharmaceuticalsAdded July 1, 2021J0225AmvuttraInjection, vutrisiran, 1 mgAlnylam PharmaceuticalsAdded January 1, 2023J0584CRYSVITAInjection, burosumab-twza 1 mgKyowa KirinAdded January 1, 2019J1203POMBILITIInjection, cipaglucosidase alfa-atga, 5 mgAmicus TherapeuticsAdded April 1, 2024J1413ELEVIDYSInjection, delandistrogene moxeparvovec-rokl, per therapeutic doseSarepta TherapeuticsAdded January 1, 2024